Our company, Biogenysis, has developed a unique and innovative approach to producing antibodies that target specific sites on viruses. This process involves using Artificial Intelligence to identify conserved and immutable targets, which we can then analyze for linearity, accessibility by antibodies, neutralizability, and the effect of mutations.
Currently, there is no cure for Cat Feline Leukemia (FeLV) virus. The cost of treatment of the virus is significant. There are more than 45 million cats in the U.S. and over 25% of households in America own one or more cats. FeLV is one of the most common infectious diseases in cats. This virus affects a significant percentage of the cat population in the United States, resulting in millions
of cats suffering from it. This same problem exists around the world in the world population of 600 million cats.
Using the Company’s Chandradrishti™ AI platform, more than 26 immutable epitope sites on the FeLV virus have been identified. These sites are claimed in the filed patent application. The patent covers the use of any of its discovered numerous conserved Feline Leukemia epitopes in the production of monoclonal antibodies, the production of vaccines, or use in diagnostic tests for detecting the virus in cats. Biogenysis, Inc. holds the exclusive license to this technology and manages this technology field for the Company. We are producing Fully Feline Monoclonal antibodies targeting these conserved targets.
For more information on our services and research projects, please click here to submit an enquiry.
